Gilteritinib
MCC-20752
Phase 1 small_molecule active
Quick answer
Gilteritinib for Acute Myeloid Leukemia With FLT3/ITD Mutation is a Phase 1 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Jazz Pharmaceuticals plc
- Indication
- Acute Myeloid Leukemia With FLT3/ITD Mutation
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active